Background: Despite an increase in the number of therapies available to treat patients with
immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist …

Abstract The 2019 American Society of Hematology (ASH) guidelines for immune
thrombocytopenia (ITP) included recommendations on the management of adults …

Abstract In 1996 and 2011, the American Society of Hematology (ASH) supported efforts to
create guidelines for the diagnosis and management of patients with immune …

Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the
American Society of Hematology published a landmark guidance paper designed to assist …

Over the last decade, there have been numerous developments and changes in treatment
practices for the management of patients with immune thrombocytopenia (ITP). This article is …

Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized
by isolated thrombocytopenia caused by increased platelet destruction and impaired platelet …

Immune thrombocytopenia (ITP) is an autoimmune process resulting in increased
destruction and inadequate production of platelets that can result in bleeding, fatigue, and …

Previously published guidelines for the diagnosis and management of primary immune
thrombocytopenia (ITP) require updating largely due to the introduction of new classes of …

Introduction Primary immune thrombocytopenia (ITP) is an autoimmune disorder
characterized by a low platelet count (< 100× 109/L) with an increased risk of bleeding …

Evidence-based medicine is growing in immune thrombocytopenia (ITP), but solid clinical
data are still lacking in many areas. A majority of children has self-limited ITP, but chronic …